Granules India Ltd
Granules India Ltd and its subsidiaries are primarily involved in the manufacturing and selling of Active Pharma Ingredients (APIs), Pharmaceutical Formulation Intermediates (PFIs) and Finished Dosages.[1]
- Market Cap ₹ 7,341 Cr.
- Current Price ₹ 296
- High / Low ₹ 381 / 227
- Stock P/E 14.4
- Book Value ₹ 105
- Dividend Yield 0.51 %
- ROCE 17.4 %
- ROE 17.5 %
- Face Value ₹ 1.00
Pros
- Company has delivered good profit growth of 20.5% CAGR over last 5 years
- Company's median sales growth is 16.4% of last 10 years
Cons
- Company might be capitalizing the interest cost
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Sector: Pharmaceuticals Industry: Pharmaceuticals - Indian - Bulk Drugs
Quarterly Results
Consolidated Figures in Rs. Crores / View Standalone
Profit & Loss
Consolidated Figures in Rs. Crores / View Standalone
Mar 2011 | Mar 2012 | Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | TTM | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
475 | 654 | 761 | 1,084 | 1,292 | 1,357 | 1,411 | 1,685 | 2,279 | 2,599 | 3,238 | 3,765 | 4,346 | |
418 | 575 | 676 | 925 | 1,082 | 1,081 | 1,112 | 1,406 | 1,895 | 2,073 | 2,382 | 3,038 | 3,468 | |
Operating Profit | 57 | 79 | 86 | 159 | 210 | 276 | 299 | 278 | 384 | 526 | 856 | 727 | 878 |
OPM % | 12% | 12% | 11% | 15% | 16% | 20% | 21% | 17% | 17% | 20% | 26% | 19% | 20% |
0 | 1 | 1 | 4 | 3 | 5 | 35 | 27 | 75 | 90 | 26 | 13 | 14 | |
Interest | 12 | 17 | 18 | 20 | 32 | 37 | 32 | 33 | 28 | 27 | 26 | 23 | 43 |
Depreciation | 18 | 21 | 23 | 30 | 53 | 58 | 72 | 76 | 105 | 137 | 151 | 159 | 176 |
Profit before tax | 27 | 43 | 46 | 112 | 128 | 186 | 230 | 196 | 326 | 451 | 704 | 558 | 673 |
Tax % | 22% | 30% | 30% | 33% | 29% | 33% | 28% | 32% | 27% | 26% | 22% | 26% | |
Net Profit | 21 | 30 | 33 | 75 | 91 | 123 | 165 | 133 | 236 | 335 | 549 | 413 | 508 |
EPS in Rs | 1.04 | 1.49 | 1.62 | 3.71 | 4.45 | 5.68 | 7.19 | 5.22 | 9.30 | 13.19 | 22.18 | 16.64 | 20.47 |
Dividend Payout % | 14% | 13% | 12% | 9% | 11% | 11% | 13% | 19% | 11% | 8% | 7% | 9% |
Compounded Sales Growth | |
---|---|
10 Years: | 19% |
5 Years: | 22% |
3 Years: | 18% |
TTM: | 23% |
Compounded Profit Growth | |
---|---|
10 Years: | 30% |
5 Years: | 20% |
3 Years: | 21% |
TTM: | 18% |
Stock Price CAGR | |
---|---|
10 Years: | 37% |
5 Years: | 20% |
3 Years: | 29% |
1 Year: | -5% |
Return on Equity | |
---|---|
10 Years: | 20% |
5 Years: | 19% |
3 Years: | 21% |
Last Year: | 17% |
Balance Sheet
Consolidated Figures in Rs. Crores / View Standalone
Mar 2011 | Mar 2012 | Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Sep 2022 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
20 | 20 | 20 | 20 | 20 | 22 | 23 | 25 | 25 | 25 | 25 | 25 | 25 | |
Reserves | 200 | 225 | 254 | 335 | 411 | 640 | 881 | 1,279 | 1,504 | 1,818 | 2,149 | 2,562 | 2,573 |
121 | 204 | 270 | 442 | 482 | 641 | 656 | 978 | 991 | 892 | 849 | 1,106 | 1,077 | |
95 | 123 | 138 | 195 | 289 | 260 | 319 | 388 | 458 | 487 | 690 | 819 | 1,183 | |
Total Liabilities | 436 | 571 | 683 | 992 | 1,203 | 1,563 | 1,879 | 2,670 | 2,979 | 3,223 | 3,713 | 4,512 | 4,858 |
239 | 250 | 263 | 482 | 617 | 560 | 644 | 777 | 944 | 1,204 | 1,332 | 1,541 | 1,743 | |
CWIP | 7 | 29 | 109 | 125 | 62 | 77 | 267 | 515 | 496 | 294 | 239 | 356 | 297 |
Investments | 0 | 0 | 10 | 0 | 0 | 70 | 108 | 157 | 210 | 19 | 19 | 20 | 21 |
190 | 291 | 301 | 385 | 524 | 856 | 859 | 1,222 | 1,328 | 1,706 | 2,123 | 2,594 | 2,797 | |
Total Assets | 436 | 571 | 683 | 992 | 1,203 | 1,563 | 1,879 | 2,670 | 2,979 | 3,223 | 3,713 | 4,512 | 4,858 |
Cash Flows
Consolidated Figures in Rs. Crores / View Standalone
Mar 2011 | Mar 2012 | Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
49 | 26 | 91 | 108 | 150 | 151 | 188 | -1 | 262 | 476 | 432 | 332 | |
-25 | -54 | -128 | -255 | -146 | -162 | -326 | -462 | -270 | -160 | -277 | -379 | |
-25 | 49 | 46 | 147 | 19 | 86 | 56 | 529 | -17 | -213 | -299 | 190 | |
Net Cash Flow | -1 | 20 | 10 | 0 | 24 | 75 | -82 | 66 | -25 | 103 | -144 | 143 |
Ratios
Consolidated Figures in Rs. Crores / View Standalone
Mar 2011 | Mar 2012 | Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Debtor Days | 55 | 53 | 34 | 37 | 39 | 101 | 108 | 136 | 108 | 93 | 86 | 90 |
Inventory Days | 93 | 97 | 107 | 99 | 110 | 128 | 145 | 114 | 112 | 125 | 205 | 190 |
Days Payable | 64 | 67 | 72 | 77 | 92 | 91 | 116 | 112 | 94 | 102 | 142 | 124 |
Cash Conversion Cycle | 84 | 83 | 69 | 59 | 57 | 138 | 137 | 138 | 126 | 116 | 150 | 156 |
Working Capital Days | 72 | 65 | 56 | 48 | 41 | 115 | 120 | 156 | 120 | 116 | 109 | 119 |
ROCE % | 11% | 15% | 13% | 20% | 19% | 20% | 18% | 12% | 15% | 17% | 25% | 17% |
Documents
Announcements
-
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome
16h - Transcript of the earnings conference call of the Company for Q3 of FY23
-
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome
24 Jan - Audio recording of the earnings conference call of the Company for Q3 of FY23
- Announcement under Regulation 30 (LODR)-Investor Presentation 24 Jan
- Board Meeting Outcome for Outcome Of The Board Meeting Dated January 24, 2023 24 Jan
-
Announcement under Regulation 30 (LODR)-Press Release / Media Release
24 Jan - Granules Pharmaceuticals Inc., Receives ANDA approval for Amphetamine Mixed Salts ER Capsules
Annual reports
-
Financial Year 2022
from bse
-
Financial Year 2021
from bse
-
Financial Year 2020
from bse
-
Financial Year 2019
from bse
-
Financial Year 2018
from bse
-
Financial Year 2017
from bse
-
Financial Year 2016
from bse
-
Financial Year 2015
from bse
-
Financial Year 2014
from bse
-
Financial Year 2013
from bse
-
Financial Year 2012
from bse
-
Financial Year 2011
from bse
-
Financial Year 2010
from bse
-
Financial Year 2010
from nse
-
Financial Year 2009
from nse
Concalls
-
Jan 2023Transcript PPT
-
Oct 2022Transcript PPT
-
Aug 2022Transcript PPT
-
May 2022Transcript PPT
-
Feb 2022Transcript PPT
-
Nov 2021Transcript PPT
-
Jul 2021Transcript PPT
-
Jun 2021TranscriptPPT
-
May 2021TranscriptPPT
-
May 2021Transcript PPT
-
Jan 2021Transcript PPT
-
Oct 2020Transcript PPT
-
Jul 2020Transcript PPT
-
Jun 2020Transcript PPT
-
Jan 2020Transcript PPT
-
Dec 2019TranscriptPPT
-
Oct 2019Transcript PPT
-
Jul 2019Transcript PPT
-
May 2019Transcript PPT
-
Jan 2019Transcript PPT
-
Oct 2018Transcript PPT
-
Jul 2018TranscriptPPT
-
May 2018TranscriptPPT
-
Feb 2018TranscriptPPT
-
Nov 2017TranscriptPPT
-
Aug 2017TranscriptPPT
-
May 2017TranscriptPPT
-
Jan 2017TranscriptPPT
-
Nov 2016TranscriptPPT
-
Aug 2016TranscriptPPT
-
Apr 2016TranscriptPPT
-
Jan 2016TranscriptPPT
APIs Vertical (~28% of revenues)[1]
The company is one of the global leaders in the manufacturing of paracetamol, metformin, guaifenesin, and Methocarbamol. It completed expansion of API manufacturing capacities of paracetamol, metformin and guaifenesin in FY20.[2]